136 related articles for article (PubMed ID: 4570447)
1. Double-blind crossoer clinical trial of pyridinolcarbamate in peripheral arterial disease (arteriosclerosis obliterans).
Walton KW; Craig GM; Prior P; Waterhouse JA; Skilton J
Br Heart J; 1973 Feb; 35(2):211-9. PubMed ID: 4570447
[No Abstract] [Full Text] [Related]
2. [Pyridinolcarbamate treatment of atherosclerosis obliterans analysed by toe plethysmography].
Motomiya T
Nihon Naika Gakkai Zasshi; 1970 Feb; 59(2):117-25. PubMed ID: 4910199
[No Abstract] [Full Text] [Related]
3. Clinical pharmacologic evaluation of the antiatherosclerotic agent, pyridinolcarbamate. A double-blind crossover trial in the treatment of atherosclerosis obliterans.
Shimamoto T; Atsumi T; Yamashita S; Motomiya T; Isokane N; Ishioka T; Sakuma A
Am Heart J; 1970 Jan; 79(1):5-19. PubMed ID: 4903137
[No Abstract] [Full Text] [Related]
4. A clinical trial with pyridinolcarbamate in the treatment of patients with obstructive diseases of the peripheral arteries.
Zelikovsky A; Urca I; Shaklai M; de Vries A
Jpn Heart J; 1973 Jan; 14(1):12-21. PubMed ID: 4541560
[No Abstract] [Full Text] [Related]
5. Pyridinolcarbamate, bradykinin antagonist, in patients suffering from arteriosclerosis obliterans and thromboangiitis obliterans (Buerger's disease); a preliminary report on the treatment of human atherosclerosis.
Shimamoto T; Atsumi T
Jpn Heart J; 1965 Sep; 6(5):407-15. PubMed ID: 5294603
[No Abstract] [Full Text] [Related]
6. Pyridinolcarbamate treatment of atherosclerosis obliterans analysed by toe plethysmography.
Motomiya T; Atsumi T; Isokane N; Yamashita S; Sano T
Jpn Heart J; 1970 Sep; 11(5):433-49. PubMed ID: 4921577
[No Abstract] [Full Text] [Related]
7. [Clinical evaluation of pyridinolcarbamate effect on patients with obliterating atherosclerosis (author's transl)].
Roztocil K; Oliva I; Linhart J; Prerovský I; Modr Z
Cas Lek Cesk; 1976 Aug; 115(33-34):1051-5. PubMed ID: 975177
[No Abstract] [Full Text] [Related]
8. Results obtained with prodectin in arteriosclerotic arterial obliteration of the lower extremities.
Hunyi L
Ther Hung; 1976; 24(2):67-71. PubMed ID: 982342
[No Abstract] [Full Text] [Related]
9. [Therapeutic efficacy of pyridinolcarbamate (Anginin) in patients with combined cerebral and peripheral arteriosclerosis].
Majkowski J; Lysakowska-Sernicka K; Gajewska A; Bilińska-Nigot B; Ostrowski K; Semenicki K
Neurol Neurochir Pol; 1978; 12(4):387-96. PubMed ID: 714218
[TBL] [Abstract][Full Text] [Related]
10. [Clinical and plethysmographic evaluation in patients with peripheral arteriopathies treated with pyridinolcarbamate].
Lucero Eseverri JA; Fajardo JD; Velles Aguirre L; Quijano E; Ciliberti E; Lucarelli R
Prensa Med Argent; 1970 Apr; 57(8):394-8. PubMed ID: 5517707
[No Abstract] [Full Text] [Related]
11. [Late results of the pyridinolcarbamate treatment of thrombotic obliterating arterial diseases of the extremities].
Fisanovich TI; Tolstova LG
Khirurgiia (Mosk); 1979 Sep; (9):76-80. PubMed ID: 502312
[No Abstract] [Full Text] [Related]
12. The effect of pyridinolcarbamate after acute and chronic administration in patients with atherosclerosis obliterans.
Roztocil K; Oliva J; Linhart J; Prerovský I; Modr Z
Int J Clin Pharmacol Biopharm; 1977 Mar; 15(3):135-8. PubMed ID: 844932
[TBL] [Abstract][Full Text] [Related]
13. Comparison of conservative (Prodectin) treatment and surgical intervention in arteriosclerotic obliterative diseases of the lower extremities.
Hunyi L
Ther Hung; 1978; 26(2):77-80. PubMed ID: 684660
[No Abstract] [Full Text] [Related]
14. [Treatment of arteriosclerotic peripheral chronic obliterating arteriopathies (A.P.C.O.) of the lower extremities with a new pharmacologic combination].
Bagliani A; Borri P; Parravicini R
Minerva Cardioangiol; 1975 Nov; 23(11):701-10. PubMed ID: 1223674
[No Abstract] [Full Text] [Related]
15. Treatment of atherosclerosis obliterans with pyridinolcarbamate.
Atsumi T; Motomiya T; Isokane N; Shimamoto T
Jpn Heart J; 1971 Jul; 12(4):335-46. PubMed ID: 5314713
[No Abstract] [Full Text] [Related]
16. [A double blind crossover trial in pyridinolcarbamate treatment of atherosclerosis obliterans].
Yamashita S
Nihon Naika Gakkai Zasshi; 1969 Apr; 58(4):283-92. PubMed ID: 4896659
[No Abstract] [Full Text] [Related]
17. [Effect of pyridinolcarbamate on blood coagulation and thrombolysis in patients with arteriosclerosis obliterans].
Hess H; Goossens N; Keil-Kuri E; Zollner R; Meyer A
Vasa; 1972; 1(3):206-11. PubMed ID: 5076123
[No Abstract] [Full Text] [Related]
18. A multiclinic double-blind trial of pyridinolcarbamate and inositol niacinate in ischemic ulcer due to chronic arterial occlusion.
Mishima Y; Kamiya K; Sakaguchi S; Kusaba A; Sakuma A
Angiology; 1977 Feb; 28(2):84-94. PubMed ID: 326097
[TBL] [Abstract][Full Text] [Related]
19. Experimental investigation of hypolipidemic and anti-atherosclerotic drugs with different mechanism of action.
Klimov AN; Ryzhenkov VE; Petrova LA; Polyakova ED
Adv Exp Med Biol; 1977; 82():477-82. PubMed ID: 920403
[No Abstract] [Full Text] [Related]
20. The effect of pyridinolcarbamate on the vasodilator action of bradykinin in the human forearm.
Ludbrook J; Vincent AH; Walsh JA
Aust J Exp Biol Med Sci; 1973 Jun; 51(3):405-9. PubMed ID: 4766561
[No Abstract] [Full Text] [Related]
[Next] [New Search]
